1. DNA Alkylation of the RUNX‐Binding Sequence by CBI–PI Polyamide Conjugates**
- Author
-
Rina Maeda, Kaori Hashiya, Toshikazu Bando, Hiroshi Sugiyama, and Shinji Ito
- Subjects
Alkylation ,010405 organic chemistry ,Drug discovery ,Chemistry ,Organic Chemistry ,Imidazoles ,Cancer ,Sequence (biology) ,DNA ,General Chemistry ,010402 general chemistry ,medicine.disease ,01 natural sciences ,Catalysis ,DNA sequencing ,0104 chemical sciences ,Nylons ,DNA Alkylation ,Biochemistry ,In vivo ,Drug delivery ,medicine ,Pyrroles ,Transcription factor - Abstract
Many types of molecular targeted drugs that inhibit cancer growth by acting on specific molecules have been developed. The runt-related transcription factor (RUNX) family, which induces cancer development by binding to a specific DNA sequence, has attracted attention as a new target for cancer treatment. We have developed Chb-M ¢ , which targets the RUNX-binding sequence. Chb-M ¢ was developed by conjugating pyrrole-imidazole (PI) polyamides and chlorambucil as an anticancer agent. It was recently reported that Chb-M ¢ had a remarkable anticancer effect in vivo. In this study, to explore the possibility of an alternative structure, we designed a new series of CBI-PI polyamides, in which seco-CBI was applied as a DNA-alkylating agent. We examined the characteristics of the CBI-PI polyamides targeting the RUNX-binding sequence and found that these conjugates have great potential for cancer treatment.
- Published
- 2020
- Full Text
- View/download PDF